BIOCHEMICAL SOCIETY TRANSACTIONS
assay with an N-terminal-directed antiserum K4023 (Heding et al., 1976) , and increased at least 5-fold after instillation of nutrients. The corresponding plasma concentrations measured with a C-terminally-directed antiserum 30K (Harris et al., 1979) increased only slightly. Consistent with the previous report of Valverde et al. (1970) , the glucagon-like polypeptides from both tissues and plasma were separated by gel filtration into poorly resolved peaks in the 800&12000 (peak I) and 3000-5000 (peak II) molecular-weight zones. A peak of immunoreactivity of molecular weight smaller than glucagon was also observed in the chromatograms of plasma and may represent proteolyticdegradation products. As shown in Fig. l(a) , the glucagon-like polypeptides in gut extracts were isoelectrically focused into components with approximate PI values of 4.7, 5.1, 6.1 and 6.9 (peak I) and 8.7 and 9.6 (peak 11), and, as shown in Figure l(b) , the immunoreactive polypeptides isolated from plasma were resolved into major components with pl values of 6.9, 7.8 and 9.4, together with minor components with PI values of 4.8, 5.3 and 5.9. Thus, the molecular heterogeneity of the glucagon-like material in gut extracts is also found in plasma.
Previous studies have demonstrated that larger-molecularweight glucagon-like polypeptides with PI values in the range 4-8, isolated from gut extracts, are devoid of glucagon-like biological effects on hepatic metabolism (Murphy et al., 1973; Holst, 1977; Conlon et al., 1979) , but that the smaller basic (PI > 9) components bind to receptor sites specific for glucagon in hepatic plasma membranes, activate adenylate cyclase and stimulate glycogenolysis with approximately one-tenth of the potency of glucagon (Bataille et al., 1974; Sasaki et al., 1975; Holst, 1977) . The present study has shown that small basic components of glucagon-like immunoreactive material are released into the circulation in response to nutrients and may thus be of importance in the regulation of carbohydrate metabolism. These components may play a role, together with pancreatic glucagon, in moderating the insulin-induced hypoglycaemic response to ingested nutrients and may be of particular importance in pancreatectomized man. The physiological role of the larger more acidic immunoreactive polypeptides, which represent the predominant forms released into the circulation, is unknown, but speculation has arisen that they may exercise an inhibitory effect on gut motility and a trophic effect on gastrointestinal mucosa (Bloom, 1972 properties. An increase in the glycoprotein output in gastric juice has been reported with various stimuli, including gastrin and secretin (Vagne & Perret, 1976) . However, this may not reflect a genuine stimulation of mucus secretion, but an increase in degraded glycoprotein subunit in the gastric juice as a result of peptic erosion of the mucus gel. In the present study we compared changes in the glycoprotein concentration in gastric juice with the specific viscosity of the juice, and relate these to changes in the relative amounts of glycoprotein polymer (characteristic of the gel) and degraded subunit formed by pepsin ( Fig. 1 ). Experiments were carried out in six conscious cats prepared with gastric fistulae (Hirst et al., 1978) . Pentagastrin and secretin were infused intravenously. Gastric secretion was collected continuously by gravity drainage and divided into pooled 15 min samples from all cats.
Pentagastrin infused alone produced pooled gastric-juice volumes of 48, 62, 60, 48, 47, 49 and 40mV15min per six cats. The specific viscosities were below 0.06 for all samples. Addition of secretin to the pentagastrin infusion resulted in a 10-fold rise in specific viscosity (Fig. 1) . Secretin did not influence the volume of secretion. The secretin-induced rise in specific viscosity could have resulted from either an increase in glycoprotein concentration and/or an increase in the relative amount of polymeric high-viscosity glycoprotein compared with the pepsin-degraded low-viscosity subunit. Glycoprotein concentrations were similar during infusion of pentagastrin alone, and infusion with pentagastrin plus secretin. However, the specific viscosity was only high when secretin was present (Fig. 1) . This signifies that there must be a change in the structure of the glycoprotein, and this is exemplified by the large difference in the reduced specific viscosities (specific viscosity/glycoprotein concentration) for essentially the same glycoprotein concentrations (cf. Fig. 1, 30 and 90min values) .
Gel filtration of gastric-juice samples on Sepharose 2B (Mantle & Allen, 1978) showed all samples to contain highmolecular-weight mucus glycoprotein polymer and lowermolecular-weight pepsin-degraded subunit. However, in samples of high viscosity, i.e. during secretin infusion, the ratio of glyco- protein polymer to degraded subunit was much greater than in low-viscosity samples during infusion of pentagastrin alone. Over a period of time, endogenous pepsin split the glycoprotein polymer into subunits, and this was accompanied by a decrease in the viscosity of the juice. The increased viscosity with secretin infusion cannot be explained by a decrease in pepsin activity, since this doubled during the secretin infusion: also, the viscosity contribution from the pepsin was negligible.
In conclusion, the mucus glycoprotein seen on infusion with pentagastrin alone is associated with predominately degraded glycoprotein subunits, and a low viscosity. This probably reflects the extra volume of gastric juice washing out previously degraded mucus from the stomach. With secretin, however, there is a large rise in the reduced and specific viscosity, and in the undegraded polymeric glycoprotein characteristic of the gel. This rise in undegraded glycoprotein in the juice, assuming no increase in mechanical erosion, is compatible with a genuine increase in mucus-gel secretion stimulated by secretin. These results also emphasize that measurements of the glycoprotein concentration or output in gastric juice alone cannot be directly equated with changes in the amount of the surface mucus gel.
We thank Dr. B. Shaw for pepsin analyses, Mr. K. Elliott for expert technical assistance, and the Science Research Council for financial support. Several gastrointestinal hormones act on the liver, and in particular on bile flow (Forker, 1977) . Somatostatin decreases bile flow and bile acid excretion in the dog (Lin et al.. 1977; Holm et al., 1978) . The response is rapid and already significant at a dosage of 0.3pg/kg body wt. per h. As somatostatin inhibits gastrin-induced gastric secretion and secretin-induced pancreatic juice, Holm et al. (1978) have speculated that it might inhibit gut hormone-induced bile secretion, but the mechanism has not been elucidated. In anaesthetized rats somatostatin had no effect on bile flow, yet the effect was pronounced on the gastric acid output (Linscheer & Raheja, 1978) . In man also, somatostatin was reported not to affect biliary volume and bilirubin excretion (Raptis et al., 1978) .
We have used two different experimental conditions in the rat to analyse the possible effect and the means of action of somatostatin on hepatocytic (canalicular) and ductular bile flow.
Male Wistar R rats weighing 300-35Og were used after they had fully recovered from anaesthesia (50mg of pentobarbital/kg body wt.) 3 h after surgical preparation of the bile duct and jugular vein when bile flow and composition are stable (Fevery et al., 1972) . In the first experimental condition different bile acid-secretion rates were obtained: 90 min. after operation group A (n = 7) received a continuous infusion of sodium taurocholate (1.5pmollkg body wt. per min) to compensate loss; group B (n = 7) received only normal saline (0.9% NaCI).
Collection of control bile started 90 rnin later. Group C (n = 6), receiving only saline, was tested 8 h after the preparation of the biliary drainage, to produce a marked decrease of bile flow and bile acid-secretion rate. In all experiments bile was collected in tared tubes over lOmin periods. The timing of the experiment comprised a 30min control period, a 60min somatostatin (Ayerst Laboratories: 20pg/kg body wt. per h; no priming dose) infusion and a 60min recovery stage. In the second condition only animals stabilized with a continuous infusion of sodium taurocholate, as in group A, were used. [''ClErythritol (The Radiochemical Centre, Amersham, Bucks., U.K.) was injected (3pCi as priming dose. followed by an infusion of O.OOBpCi/kg body wt. per rnin until the end of the experiment). Erythritol was allowed to equilibrate for 90 rnin before sampling of bile. Experimental animals (n = 7) received somatostatin for 60min as described above. Blood (300~1) was obtained through the carotid artery prepared surgically and kept open by a continuous injection of heparin (15 units/kg body wt. per h) in normal saline. It was taken at 15 and 5 rnin before, and at 35,45 and 55 rnin after, the onset of somatostatin infusion; samples at 65 and 75min after discontinuation of the infusion (recovery phase) were also obtained. Animals infused only with saline (n = 5 ) were used as controls (sham infusion).
The overall effect of somatostatin can be divided into two parts: an early phase, already significant at the end of the first IOmin, where the bile flow and bile acid output decreased progressively, and a steady state, from 30min to the end of the infusion. In the early phase the ratio of bile acid concen-' tration/bile flow remained unchanged. Further data refer only to the steady state, where the maximal display of the cholestatic
